Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp. implemented a 1-for-15 reverse share split on July 29, 2025. The stock surged by 38.4% on July 31, 2025, following the announcement of a new CEO and FDA clearance for a diagnostic product. In August 2025, the stock experienced a 24.14% surge due to preclinical results for SIL204 and a collaboration with Catalent. On September 11, 2025, the company announced the pricing of a $6.0 million public offering, with the stock soaring by 190% in pre-market trading due to positive preclinical data for SIL204. The company regained compliance with Nasdaq listing requirements on September 25, 2025. On September 30, 2025, Silexion Therapeutics announced positive new human cell line data confirming pan-KRAS activity of SIL204. Silexion Therapeutics reported its Third Quarter 2025 financial results and provided a business update on November 12, 2025. The company successfully completed toxicology studies for SIL204 on November 25, 2025. In December 2025, the stock experienced its lowest probability of a positive return, according to seasonality analysis. On January 6, 2026, Silexion Therapeutics released a CEO letter to shareholders highlighting 2025 achievements and outlining upcoming milestones for 2026. Overall, the stock price has seen a significant decline of 92.75% over the last year.

Information regarding the demand seasonality for Silexion Therapeutics Corp.'s products and services is not explicitly available, but stock performance seasonality indicates April has the highest probability of a positive return and December has the lowest, reflecting stock market trends rather than direct product demand.

Silexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for unmet medical needs, particularly in oncology, utilizing RNA interference (RNAi)-based cancer drugs and proprietary delivery systems like its LODER platform to treat malignant solid tumors. Its major products and pipeline candidates include SiG12D-LODER, Prostate-LODER, GBM-LODER, SIL-204, Silexion-101, Silexion-202, Silexion-303, Neurolex, Parkinex, and Rarelex. The company's business model integrates research, clinical development, and strategic partnerships, generating revenue through therapy sales, licensing agreements, and collaborations.

Silexion Therapeutics Corp. was founded in 2008 and is headquartered in Jerusalem, Israel, with its principal executive offices located at 12 Abba Hillel Road, Ramat-Gan, Israel.

Specific news or analysis directly addressing Silexion Therapeutics Corp.'s brand reputation in the past year is not readily available in the provided search results.

Silexion Therapeutics Corp. has 12 institutional owners and shareholders holding a total of 5,085 shares, with major institutional shareholders including Montag A & Associates Inc., SBI Securities Co., Ltd., UBS Group AG, and Pflug Koory, LLC, owning 10.95% of the stock. Major individual shareholders include Ilan Levin, who owns 2.88 million shares, representing 91.95% of the company, and other insider owners include Shlomo Noy, Avner Lushi, Amnon Peled, and Ruth Alon, with positive insider sentiment as 5 different insiders bought shares over the last year.